Spyre Therapeutics, Inc.
SYRE
Positions held
Your positionsSYRE isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Spyre Therapeutics operates in the biotechnology sector, which is known for its potential to deliver groundbreaking therapies and high returns for investors as innovative treatments gain regulatory approval.
- Spyre Therapeutics has a market capitalization of approximately $7.06 billion, indicating strong investor interest and potential for growth.
- The company's target mean price is $120.21, suggesting significant upside potential from its current trading levels.
- Spyre Therapeutics has reported no revenue in recent quarters, which raises concerns about its ability to sustain operations and attract further investment.
- The company has a negative profit margin of 0.0%, indicating it is currently unprofitable and struggling to generate income.
- Spyre's score indicates a 'Strong Sell' signal with a score of -26.00, reflecting negative trends and investor sentiment.
Fundamentals
| Market cap | $7.37B | Enterprise value | $6.05B | Trailing P/E | — | Forward P/E | -22.70 |
| PEG | — | Price / book | 7.37 | Beta | 3.11 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -23.0% | ROA | -19.8% | Debt / equity | — |
| Current ratio | 18.53 | Free cash flow | -$89.05M | Analyst recommendation | strong_buy | Mean target | $120.21 |
| 52w high | $110.18 | 52w low | $17.65 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — | — |
| Net income | -$36.2M | -$69.0M | -$62.5M | -$11.2M | -$36.7M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$81.6M | -$75.6M | -$57.2M | -$56.9M | -$51.9M |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.9M | $2.3M |
| Op margin | — | — | -14510.6% | -3640.2% |
| Net income | -$155M | -$208M | -$339M | -$83.8M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$220M | -$209M | -$129M | -$84.8M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Spyre Therapeutics (SYRE) Completed A $350 Million Public Stock Offering
2026-10-06 · Update: Spyre Shares Fall After Pricing $350 Million Stock Offering
2026-10-06 · Spyre Therapeutics Sinks 14% on Upsized $350 Million Stock Offering Priced Below Market
2026-10-06 · Spyre Therapeutics Prices $350 Million Common Stock Offering; Shares Down Pre-Bell
2026-10-06 · Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
2026-10-05 · Spyre Therapeutics stock falls on public offering launch
2026-10-05 · Spyre Therapeutics Commences Public Offering of Common Stock
2026-10-05 · Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
2026-10-05 · Spyre Therapeutics Insider Sold Shares Worth $2,261,831, According to a Recent SEC Filing
2026-10-02 · Spyre Therapeutics Announces Grants of Inducement Awards
2026-10-01 · Exxon Mobil downgraded, BP upgraded: Wall Street's top analyst calls
2026-10-01 · JPMorgan Initiates Spyre Therapeutics at Overweight With $110 Price Target
Price (daily)
Full chart · RSI · MACD · patterns